161.13 USD
+0.88 (+0.55%)
161.13 USD
0 (0%)
JAZZ gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of JAZZ while its profitability can be described as average. A decent growth rate in combination with a cheap valuation! Better keep an eye on JAZZ.
1. Profitability
1.1 Basic Checks
JAZZ had positive earnings in the past year.
In the past year JAZZ had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
Each year in the past 5 years JAZZ had a positive operating cash flow.
1.2 Ratios
JAZZ has a better Return On Assets (-3.24%) than 74.21% of its industry peers.
JAZZ's Return On Equity of -9.31% is fine compared to the rest of the industry. JAZZ outperforms 74.74% of its industry peers.
JAZZ has a better Return On Invested Capital (3.95%) than 82.11% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 12.84%.
The last Return On Invested Capital (3.95%) for JAZZ is above the 3 year average (3.85%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROIC | 3.95% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
JAZZ's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 10.92%, JAZZ belongs to the top of the industry, outperforming 83.16% of the companies in the same industry.
In the last couple of years the Operating Margin of JAZZ has declined.
JAZZ has a Gross Margin of 88.49%. This is amongst the best in the industry. JAZZ outperforms 90.00% of its industry peers.
JAZZ's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
JAZZ has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
JAZZ has less shares outstanding than it did 1 year ago.
The number of shares outstanding for JAZZ has been increased compared to 5 years ago.
JAZZ has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.50, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
JAZZ's Altman-Z score of 1.50 is in line compared to the rest of the industry. JAZZ outperforms 55.79% of its industry peers.
JAZZ has a debt to FCF ratio of 4.33. This is a neutral value as JAZZ would need 4.33 years to pay back of all of its debts.
JAZZ has a better Debt to FCF ratio (4.33) than 83.68% of its industry peers.
JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of JAZZ (1.09) is worse than 74.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.5 |
ROIC/WACC0.54
WACC7.35%
2.3 Liquidity
JAZZ has a Current Ratio of 1.65. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
JAZZ's Current ratio of 1.65 is on the low side compared to the rest of the industry. JAZZ is outperformed by 68.95% of its industry peers.
JAZZ has a Quick Ratio of 1.44. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
JAZZ's Quick ratio of 1.44 is on the low side compared to the rest of the industry. JAZZ is outperformed by 64.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
JAZZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.39%.
JAZZ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.47% yearly.
JAZZ shows a small growth in Revenue. In the last year, the Revenue has grown by 4.14%.
The Revenue has been growing by 13.48% on average over the past years. This is quite good.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
3.2 Future
Based on estimates for the next years, JAZZ will show a small growth in Earnings Per Share. The EPS will grow by 7.67% on average per year.
JAZZ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.06% yearly.
EPS Next Y-61.17%
EPS Next 2Y4.25%
EPS Next 3Y6.22%
EPS Next 5Y7.67%
Revenue Next Year4.61%
Revenue Next 2Y5.53%
Revenue Next 3Y6.22%
Revenue Next 5Y7.06%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 19.75, which indicates a rather expensive current valuation of JAZZ.
Compared to the rest of the industry, the Price/Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 81.05% of the companies listed in the same industry.
JAZZ's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.19.
A Price/Forward Earnings ratio of 7.00 indicates a rather cheap valuation of JAZZ.
JAZZ's Price/Forward Earnings ratio is rather cheap when compared to the industry. JAZZ is cheaper than 92.63% of the companies in the same industry.
JAZZ's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.75 | ||
| Fwd PE | 7 |
4.2 Price Multiples
85.79% of the companies in the same industry are more expensive than JAZZ, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 94.21% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.9 | ||
| EV/EBITDA | 10.87 |
4.3 Compensation for Growth
The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.61
EPS Next 2Y4.25%
EPS Next 3Y6.22%
5. Dividend
5.1 Amount
JAZZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
161.13
+0.88 (+0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners104.02%
Inst Owner Change0.21%
Ins Owners2.48%
Ins Owner Change-0.78%
Market Cap9.79B
Revenue(TTM)4.16B
Net Income(TTM)-368.48M
Analysts85.22
Price Target217.63 (35.06%)
Short Float %8.56%
Short Ratio4.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)2.57%
PT rev (3m)14.13%
EPS NQ rev (1m)-0.24%
EPS NQ rev (3m)11.36%
EPS NY rev (1m)-0.12%
EPS NY rev (3m)53.06%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-0.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.75 | ||
| Fwd PE | 7 | ||
| P/S | 2.36 | ||
| P/FCF | 7.9 | ||
| P/OCF | 7.04 | ||
| P/B | 2.47 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.87 |
EPS(TTM)8.16
EY5.06%
EPS(NY)23.03
Fwd EY14.29%
FCF(TTM)20.39
FCFY12.65%
OCF(TTM)22.9
OCFY14.21%
SpS68.42
BVpS65.15
TBVpS-40.06
PEG (NY)N/A
PEG (5Y)3.61
Graham Number109.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROCE | 5% | ||
| ROIC | 3.95% | ||
| ROICexc | 5.1% | ||
| ROICexgc | 55.75% | ||
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% | ||
| FCFM | 29.8% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Debt/EBITDA | 3.8 | ||
| Cap/Depr | 22.29% | ||
| Cap/Sales | 3.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 122.16% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.5 |
F-Score5
WACC7.35%
ROIC/WACC0.54
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-61.17%
EPS Next 2Y4.25%
EPS Next 3Y6.22%
EPS Next 5Y7.67%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.61%
Revenue Next 2Y5.53%
Revenue Next 3Y6.22%
Revenue Next 5Y7.06%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-59.85%
EBIT Next 3Y5.83%
EBIT Next 5Y7.65%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.
Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a valuation rating of 7 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.
Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.
Can you provide the financial health for JAZZ stock?
The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.
What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -61.17% in the next year.